NHS drug pricing is all about the art of the deal | Letter
The article discusses the challenges of NHS drug pricing and negotiation with pharmaceutical companies. It acknowledges that the process can be a "special circle of hell," but suggests that better negotiation could ease the situation. The article notes that new drugs are rarely cheaper than existing ones, so the NHS must focus on finding drugs that offer meaningful improvements in patient outcomes. It states that the National Institute for Health and Care Excellence (NICE) recommends the majority of newly licensed drugs, as they provide some useful benefits, even if they don't represent a revolutionary breakthrough. The author argues that with more effective negotiation, the NHS can strike a better balance between access to new treatments and managing costs.
Source: For the complete article, please visit the original source link below.
